Friday, 14 February 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 14 February 2025
News

Hiring for game-changer product

 Posted 31 July 2024 AM

ASX-listed LTR Pharma is ploughing big dollars into launch plans for its game-changing nasal spray for the treatment of erectile dysfunction as it looks to secure a partnership deal with Big Pharma for global commercialisation of the product.

The company said it will use $10.5 million from a special funding raising to expedite commercialisation of its product Spontan, channelling $2 million into sales and marketing, $1 million into a telemedicine consumer website, $2 million to expand its R&D pipeline and $1.4 million on regulatory studies. The balance will go into working capital and to cover the costs of the offer.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (14)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (4)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.